<DOC>
	<DOCNO>NCT00551343</DOCNO>
	<brief_summary>The purpose study investigate effect GLP-1 agonist satiety hormone patient Prader-Willi Syndrome ( genetic defect cause obesity ) .</brief_summary>
	<brief_title>Gut Derived Hormones , Body Composition Metabolism Prader-Willi Syndrome</brief_title>
	<detailed_description>Prader-Willi Syndrome ( PWS ) frequent know genetic disorder obesity . Hyperphagia main barrier independent living adult PWS , hitherto behavioural restraint environmental modification effective management measure . The emerge cost professional care immense . Thus , urgent need treatment reduce appetite food intake patient group . Agonists gut derive hormone GLP-1 reduces food intake cause weight loss due slow gastric empty direct central effect . The aim pilot drug trial analyse effect GLP-1 agonist appetite regulate hormone , insulin secretion energy expenditure meal .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>see Diabetes mellitus , acute infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>